Endothelial stress ratio as a predictor of the no-reflow phenomenon in patients with acute coronary syndrome: a retrospective study
Department of Cardiology, Erzurum City Hospital, Erzurum, Türkiye
Department of Cardiology, Faculty of Medicine, Ataturk University Erzurum, Türkiye
Article file
- Morishima I, Sone T, Okumura K, et al. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 2000; 36: 1202-9.
- Niccoli G, Scalone G, Lerman A, Crea F. Coronary microvascular obstruction in acute myocardial infarction. Eur Heart J 2016; 37: 1024-33.
- Heusch G. Coronary microvascular obstruction: the new frontier in cardioprotection. Basic Res Cardiol 2019; 114: 45.
- Kloner RA. No-reflow phenomenon: maintaining vascular integrity. J Cardiovasc Pharmacol Ther 2011; 16: 244-50.
- Nicolau AM, Silva PG, Mejía HPG, et al. Molecular mechanisms of microvascular obstruction and dysfunction in percutaneous coronary interventions: from pathophysiology to therapeutics a comprehensive review. Int J Mol Sci 2025; 26: 6835.
- Zhao Y, Yang J, Ji Y, et al. Usefulness of fibrinogen-to-albumin ratio to predict no-reflow and short-term prognosis in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Heart Vessels 2019; 34: 1600-7.
- Refaat H, Tantawy A, Gamal AS, et al. Novel predictors and adverse long-term outcomes of no-reflow phenomenon in patients with acute ST elevation myocardial infarction undergoing primary PCI. Indian Heart J 2021; 73: 35-43.
- Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation 2002; 105: 656-62.
- Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial no-reflow in humans. J Am Coll Cardiol 2009; 54: 281-92.
- Ito H. No-reflow phenomenon and prognosis in acute myocardial infarction. Nat Clin Pract Cardiovasc Med 2006; 3: 499-506.
- Wang W, Ren D, Wang CS, et al. Prognostic efficacy of high-sensitivity C-reactive protein to albumin ratio in patients with acute coronary syndrome. Biomarkers Med 2019; 13: 811-20.
- Libby P, Loscalzo J, Ridker PM, et al. Inflammation, immunity, and infection in atherothrombosis: JACC review topic of the week. J Am Coll Cardiol 2018; 72: 2071-81.
-
Harrison RW, Aggarwal A, Ou FS, et al. Incidence and outcomes of
no-reflow phenomenon during percutaneous coronary intervention among
patients with acute myocardial infarction. Am
J Cardiol 2013; 111: 178-84. - Zhang L, Lin J, Luo L, et al. Analysis of risk factors for PCI no-reflow in coronary heart disease and construction of related prediction models. Am J Transl Res 2024; 16: 3733-41.
- Prasad A, Gersh BJ. Management of microvascular dysfunction and reperfusion injury. Heart 2005; 91: 1530-2.
- Ridker PM, Everett BM, Thuren T, et al. Anti-inflammatory therapy with canakinumab and prevention of cardiovascular events. N Engl J Med 2017; 377: 1119-31.
- Libby P. Inflammation in atherosclerosis. J Am Coll Cardiol 2009; 54: 2129-38.
- Marcus ML, Chilian WM, Kanatsuka H, et al. Understanding the coronary circulation through studies at the microvascular level. Circulation 1990; 82: 1-7.
Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
